A delicate balancing act for Immunogen
The group is desperately playing up mirvetuximab, but its future rests with a pair of earlier-stage projects.
Astra and Daiichi lay out their plan for a better Herceptin
The companies’ DS-8201 succeeds in breast cancer patients who had failed Kadcyla, and will go before the regulators later this year.
Immunogen fails to leap Forward
As doubts grow about targeting the folate receptor, Immunogen’s decision to press on with mirvetuximab soravtansine looks desperate.
Ash 2018 – Immunogen makes its case for a Jazz gig
The first day of the haematology conference sees first-in-human data from two antibody-drug conjugates belonging to Immunogen, a company eager to draw a line under a…
Ash 2018 preview – blood cancers offer biotech a chance at redemption
The Ash meeting starts on December 1. Here are some haematological cancer presentations that investors will be focusing on, as biotech risks ending 2018 in poor shape.
Esmo 2018 – Adaptimmune gets the wooden spoon
The company emerges as the worst-performing stock after Europe’s most important cancer conference, which claims numerous other victims.
Asco 2018 event analyser – A year of reset expectations
Deciphera Pharmaceuticals emerges as one of the Asco 2018 winner as Jounce Therapeutics falls on weak data.
Back to the future for small caps, but not all benefit
Oncology-focused smaller biotechs reap rich rewards, but generics groups face hard times.
